The Relationship Between Breg Cells,Treg Cells,IL-10 And Clinical Characteristics In Patients With Ovarian Cancer

Objectives:To explore the expression frequency of CD19⁺CD24^hiCD38^hiBregs regulatory B cells（Bregs）in peripheral blood of ovarian cancer patients and its relationship with FIGO interval,and to analyze its correlation with regulatory T cells（Tregs）and IL-10.Methods:（1）According to postoperative pathological results,all patients in this study were divided into two groups,namely,benign ovarian tumor group and ovarian cancer group;（2）Flow cytometry was used to detect the expression frequency of CD19⁺CD24^hiCD38^hiBregs in PBMC of peripheral blood samples of all patients;（3）Flow cytometry was used to detect the expression frequency of CD4⁺CD25⁺Tregs cells in PBMC of peripheral blood samples of all patients;（4）The expression level of serum interleukin-10 was detected by enzyme-linked immunosorbent assay;（5）Clinicopathological data of patients were collected and analyzed to reveal the relationship between Bregs,Tregs and clinicopathological conditions.Results:（1）The percentage of Bregs in peripheral blood of patients with benign ovarian tumor was 1.68（1.49-1.89）%,and that of patients with ovarian cancer was2.27（2.04-2.56）%,showing statistical difference;（2）The percentage of Tregs in peripheral blood of patients with benign ovarian tumor was 2.60（2.33-2.86）%,and that of patients with ovarian cancer was 4.22（3.89-4.58）%,showing statistical difference;（3）The level of IL-10 in benign ovarian tumor patients was（11.068±3.233）pg/ml,and that in ovarian cancer patients was（29.026±12.462）pg/ml,showing a statistical difference;（4）Abnormal up-regulation of Bregs and Tregs in peripheral blood of ovarian cancer patients is closely related to FIGO stage in ovarian cancer patients.Conclusions:Compared with patients with benign ovarian tumor,the proportion of Bregs and Tregs in the peripheral blood of ovarian cancer patients is significantly higher,which can participate in the immune response of ovarian cancer through the secretion of IL-10 and is correlated with poor clinical stage,which may provide a new target for immunotherapy of ovarian cancer.